<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81563">
  <stage>Registered</stage>
  <submitdate>24/08/2006</submitdate>
  <approvaldate>17/10/2006</approvaldate>
  <actrnumber>ACTRN12606000443594</actrnumber>
  <trial_identification>
    <studytitle>Apricitabine (AVX754), a new nucleoside reverse transcriptase inhibitor (NRTI) to treat HIV</studytitle>
    <scientifictitle>An open label extension study to evaluate the long term safety and efficacy of apricitabine in controlling Human Immunodeficiency Virus (HIV) viral load and disease progression in treatment-experienced HIV-1 infected subjects</scientifictitle>
    <utrn />
    <trialacronym>AVX-201E</trialacronym>
    <secondaryid>AVX-201E</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study is an open label extension study of the long term safety of apricitabine in Human Immunodeficiency Virus Type 1 (HIV-1) infected subjects who have completed the AVX-201 study. Subjects will continue to receive 800mg apricitabine by mouth twice daily in addition to their other HIV medications for up to an additional 96 weeks (making 144 weeks in total). The study will measure the long term safety of continued apricitabine treatment in HIV-1 infected subjects who were part of the AVX-201 study.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to loss of virologic contro</outcome>
      <timepoint>Assessed at weeks 96 and 144</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of adverse events</outcome>
      <timepoint>Assessed at weeks 96 and 145</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in viral load</outcome>
      <timepoint>At weeks 72, 96, 120 and 144.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>HIV-1 infected males and non-pregnant, non-lactating females, when they entered the preceding AVX-201 studyCompleted the AVX-201 studyPlasma viral load &lt;5000 copies/mlCD4 cells &gt;50.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Withdrawal from AVX-201 study or major protocol violationfemale subjects who are pregnant or breastfeeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avexa Ltd</primarysponsorname>
    <primarysponsoraddress>576 Swan St Richmond VIC 3121</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Avexa Ltd</fundingname>
      <fundingaddress>576 Swan St
Richmond
VIC 3121</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will measure how safe it is to continue with apricitabine treatment long term in people with HIV-1 infection who  previously were treated with apricitabine for a shorter period in a previous study</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Albion St Clinic Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/08/2006</ethicapprovaldate>
      <hrec>EXT 05/069</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/08/2006</ethicapprovaldate>
      <hrec>H06/075</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/10/2006</ethicapprovaldate>
      <hrec>184/06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Susan Cox</name>
      <address>Avexa
576 Swan St
Richmond VIC 3121</address>
      <phone>+61 3 92084066</phone>
      <fax>+61 3 92084004</fax>
      <email>scox@avexa.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Susan Cox</name>
      <address>Avexa
576 Swan St
Richmond VIC 3121</address>
      <phone>+61 3 92084066</phone>
      <fax>+61 3 92084004</fax>
      <email>scox@avexa.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>